CheckMate 067 6.5-Yr Follow-up: Long-term Safety and Efficacy of Nivolumab and Ipilimumab for First-line Treatment of Advanced Melanoma

Source: 2021 ASCO Virtual Annual Meeting*
Download Slideset
June 4-8, 2021; Online at https://conferences.asco.org/am
CheckMate 067 6.5-year follow-up finds a median overall survival of 72.1 months with nivolumab + ipilimumab in patients with advanced melanoma, durable benefits across subgroups, and no new safety signals.
Format: Microsoft PowerPoint (.ppt)
File Size: 593 KB
Released: June 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings